174 related articles for article (PubMed ID: 37558751)
1. Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers.
Romero JM; Titmuss E; Wang Y; Vafiadis J; Pacis A; Jang GH; Zhang A; Golesworthy B; Lenko T; Williamson LM; Grünwald B; O'Kane GM; Jones SJM; Marra MA; Wilson JM; Gallinger S; Laskin J; Zogopoulos G
NPJ Precis Oncol; 2023 Aug; 7(1):73. PubMed ID: 37558751
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Infiltrating PD-1
Yang Z; Deng Y; Cheng J; Wei S; Luo H; Liu L
Front Oncol; 2021; 11():695006. PubMed ID: 34604032
[TBL] [Abstract][Full Text] [Related]
3. A 20-gene mutation signature predicts the efficacy of immune checkpoint inhibitor therapy in advanced non-small cell lung cancer patients.
Hu X; Guo J; Shi J; Li D; Li X; Zhao W
BMC Pulm Med; 2023 Jun; 23(1):223. PubMed ID: 37349743
[TBL] [Abstract][Full Text] [Related]
4. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer.
Sammons S; Elliott A; Barroso-Sousa R; Chumsri S; Tan AR; Sledge GW; Tolaney SM; Torres ETR
Front Oncol; 2023; 13():1235902. PubMed ID: 37637072
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy.
Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J
JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893
[TBL] [Abstract][Full Text] [Related]
6. Identification of the immune cell infiltration landscape in pancreatic cancer to assist immunotherapy.
Wang Z; Zou W; Wang F; Zhang G; Chen K; Hu M; Liu R
Future Oncol; 2021 Nov; 17(31):4131-4143. PubMed ID: 34346253
[TBL] [Abstract][Full Text] [Related]
7. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of PRKDC mutations and association with response to immune checkpoint inhibitors in solid tumors.
Chen Y; Li Y; Guan Y; Huang Y; Lin J; Chen L; Li J; Chen G; Pan LK; Xia X; Xu N; Chang L; Guo Z; Pan J; Yi X; Chen C
Mol Oncol; 2020 Sep; 14(9):2096-2110. PubMed ID: 32502294
[TBL] [Abstract][Full Text] [Related]
9. A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.
Long J; Wang D; Wang A; Chen P; Lin Y; Bian J; Yang X; Zheng M; Zhang H; Zheng Y; Sang X; Zhao H
Genome Med; 2022 Feb; 14(1):20. PubMed ID: 35197093
[TBL] [Abstract][Full Text] [Related]
10. Immune Determinants of the Association between Tumor Mutational Burden and Immunotherapy Response across Cancer Types.
Sinha N; Sinha S; Valero C; Schäffer AA; Aldape K; Litchfield K; Chan TA; Morris LGT; Ruppin E
Cancer Res; 2022 Jun; 82(11):2076-2083. PubMed ID: 35385572
[TBL] [Abstract][Full Text] [Related]
11. Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase.
Valero C; Lee M; Hoen D; Zehir A; Berger MF; Seshan VE; Chan TA; Morris LGT
JAMA Oncol; 2021 May; 7(5):739-743. PubMed ID: 33599686
[TBL] [Abstract][Full Text] [Related]
12. PTPRD/PTPRT mutation as a predictive biomarker of immune checkpoint inhibitors across multiple cancer types.
Shang X; Zhang W; Zhang X; Yu M; Liu J; Cheng Y; Cheng B
Front Immunol; 2022; 13():991091. PubMed ID: 36248841
[TBL] [Abstract][Full Text] [Related]
13. Association of MUC16 Mutation With Response to Immune Checkpoint Inhibitors in Solid Tumors.
Zhang L; Han X; Shi Y
JAMA Netw Open; 2020 Aug; 3(8):e2013201. PubMed ID: 32845327
[TBL] [Abstract][Full Text] [Related]
14. Combination of TMB and CNA Stratifies Prognostic and Predictive Responses to Immunotherapy Across Metastatic Cancer.
Liu L; Bai X; Wang J; Tang XR; Wu DH; Du SS; Du XJ; Zhang YW; Zhu HB; Fang Y; Guo ZQ; Zeng Q; Guo XJ; Liu Z; Dong ZY
Clin Cancer Res; 2019 Dec; 25(24):7413-7423. PubMed ID: 31515453
[TBL] [Abstract][Full Text] [Related]
15. Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary.
Posner A; Sivakumaran T; Pattison A; Etemadmoghadam D; Thio N; Wood C; Fisher K; Webb S; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Fellowes A; Fox SB; Hicks RJ; Schofield P; Bowtell D; Prall OWJ; Tothill RW; Mileshkin L
J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36720497
[TBL] [Abstract][Full Text] [Related]
16.
Ji W; Niu X; Yu Y; Li Z; Gu L; Lu S
Front Immunol; 2022; 13():955800. PubMed ID: 36405701
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer.
Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N
JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449
[TBL] [Abstract][Full Text] [Related]
18. A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer.
Romero JM; Grünwald B; Jang GH; Bavi PP; Jhaveri A; Masoomian M; Fischer SE; Zhang A; Denroche RE; Lungu IM; De Luca A; Bartlett JMS; Xu J; Li N; Dhaliwal S; Liang SB; Chadwick D; Vyas F; Bronsert P; Khokha R; McGaha TL; Notta F; Ohashi PS; Done SJ; O'Kane GM; Wilson JM; Knox JJ; Connor A; Wang Y; Zogopoulos G; Gallinger S
Clin Cancer Res; 2020 Apr; 26(8):1997-2010. PubMed ID: 31964786
[TBL] [Abstract][Full Text] [Related]
19. New evaluation of the tumor immune microenvironment of non-small cell lung cancer and its association with prognosis.
Shinohara S; Takahashi Y; Komuro H; Matsui T; Sugita Y; Demachi-Okamura A; Muraoka D; Takahara H; Nakada T; Sakakura N; Masago K; Miyai M; Nishida R; Shomura S; Shigematsu Y; Hatooka S; Sasano H; Watanabe F; Adachi K; Fujinaga K; Kaneda S; Takao M; Ohtsuka T; Yamaguchi R; Kuroda H; Matsushita H
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35396225
[TBL] [Abstract][Full Text] [Related]
20. Integrating tumor mutational burden and transcriptome expression into prediction of immune checkpoint inhibitor response and prognosis of patients with colon cancer.
Liang L; Jiang W; Zheng Y; Liu TS; Shen XZ; Chen YJ
J Physiol Pharmacol; 2022 Apr; 73(2):. PubMed ID: 35988929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
